Monopar Therapeutics Inc.
MNPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,590 | $1,730 | $1,643 | $9,925 |
| G&A Expenses | $0 | $1,504 | $1,578 | $0 |
| SG&A Expenses | $1,503 | $1,504 | $1,578 | $1,150 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,093 | $3,234 | $3,222 | $11,075 |
| Operating Income | -$4,093 | -$3,234 | -$3,222 | -$11,075 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $655 | $781 | $597 | $149 |
| Pre-Tax Income | -$3,438 | -$2,454 | -$2,625 | -$10,926 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,438 | -$2,454 | -$2,625 | -$10,926 |
| % Margin | – | – | – | – |
| EPS | -0.48 | -0.35 | -0.38 | -0.95 |
| % Growth | -37.1% | 7.9% | 60% | – |
| EPS Diluted | -0.48 | -0.35 | -0.38 | -0.95 |
| Weighted Avg Shares Out | 7,124 | 6,998 | 6,907 | 11,444 |
| Weighted Avg Shares Out Dil | 7,124 | 6,998 | 6,987 | 11,484 |
| Supplemental Information | – | – | – | – |
| Interest Income | $655,473 | $781 | $597 | $149 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3,438 | -$2,454 | -$3,222 | -$10,926 |
| % Margin | – | – | – | – |